Thursday 25 February 2016, Amsterdam
The report, now available on ASDReports, recognizes the following companies as the key players in the Global Oncology Biosimilars Market: Biocon, Celltrion, Dr. Reddy’s Laboratories, F. Hoffmann-La Roche, Hospira, Mylan and Sandoz.
Other Prominent Vendors in the market are: AbbVie, Allergan, Amgen, AstraZeneca, Baxter, Biogen, BioXpress Therapeutics, Boehringer Ingelheim, Cipla, Coherus BioSciences, Coherus BioSciences, Daiichi Sankyo, Emcure Pharmaceuticals, GlaxoSmithKline (GSK), Intas Pharmaceuticals, Merck, Pfizer, Sanofi, 3SBio and Wockhardt.
Commenting on the report, an analyst said: “It is expected that the trend of outsourcing drug manufacturing to developing countries to have a significant impact on the market. Outsourcing the production of biosimilars reduced the overall cost of manufacturing biosimilars, making them affordable.”
According to the report, a number of biological patents are either about to expire during the forecast period or have already expired. The patent expiries of branded drugs results in the entry of less expensive biosimilars, boosting the market growth.
Further, the report states that the risk related to the failure of the drugs and the high investment needed during the developmental stage hampers the growth of the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News